Advertisement

Immunosuppressive Agents

  • Manzoor M. Khan
Chapter

Introduction

Successful organ transplantation requires effective immunosuppression. Most of the modern advances in tissue transplantation have resulted from our precise understanding of the immune mechanisms involved in tissue rejection as well as from advances in surgical techniques to some degree. The last decade has witnessed the introduction of several potent immunosuppressive agents, which have led to considerable success in transplant medicine. The development of effective immunosuppressive therapy has been essential in tissue transplantation and for improvements in its positive outcome. Great advances have been made over the past 50 years in organ transplantation despite the complexities involved in immune suppression after tissue transplantation. The development of novel immunosuppressive agents has increased the graft survival rates; however, the side effects of these drugs resulting from their long-term use continue to present significant challenges. In addition to organ...

Keywords

Acute Rejection Immunosuppressive Agent Mycophenolate Mofetil Calcineurin Inhibitor Antithymocyte Globulin 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Bibliography

  1. Ballow M. 1997. Mechanism of action of intravenous serum immunoglobulin in autoimmune and inflammatory diseases. J All Clin Immunol. 100:151–157.CrossRefGoogle Scholar
  2. Boratynska M, Banasik M, Patrzalek D, Klinger M. 2006. Conversion from cyclosporine-based immunosuppression to tacrolimus/mycophenolate mofetil in patients with refractory and ongoing acute renal allograft rejection. Ann Transplant. 11:51–56.PubMedGoogle Scholar
  3. Borel JF. 2002. History of the discovery of cyclosporin and its early pharmacologic development. Wien Klin Wochenschr. 114/12:433–437.Google Scholar
  4. Bowman JM. 1990. RhD hemolytic disease of the newborn. NEJM. 339:1775–1777.CrossRefGoogle Scholar
  5. Brinkmann V, Pinschewer PD, Feng L, Chen S. 2001. FTY720: Altered lymphocyte traffic results in allograft protection. Transplantation. 72:764–769.PubMedCrossRefGoogle Scholar
  6. Brinkmann V, Lynch KR. 2002. FTY720: Targeting G-protein coupled receptors for sphingosine 1-phosphate in transplantation and autoimmunity. Curr Opin Immunol. 14:569–575.PubMedCrossRefGoogle Scholar
  7. Brinkmann V, Cyster JG, Hla T. 2004. FTY720: Sphingosine 1-phosphate receptor in the control of lymphocyte egress and endothelial barrier function. Amer J Transplant. 4:1019–1025.CrossRefGoogle Scholar
  8. Brochstein JA, Kernan NA, Groshen S, Cirricione C, et al. 1987. Allogenic bone marrow transplantation after hyperfractionated total body irradiation and cyclophosphamide in children with acute leukemia. NEJM. 317:1618–1624.PubMedCrossRefGoogle Scholar
  9. Brown EJ, Albers MW, Shin TB, Ichikawa K, et al. 1994. A mammalian protein targeted by G1-arresting rapamycin-receptor complex. Nature. 369:756–758.PubMedCrossRefGoogle Scholar
  10. Budde K, Schutz M, Glander P, Peters H, et al. 2006. FTY720 (fingolimod) in renal transplantation. Clin Transplant. 20:17–24.PubMedCrossRefGoogle Scholar
  11. Burke JF, Pirsch JD, Ramos EL, Salomon DR, et al. 1994. Long term safety and efficacy of cyclosporine in renal transplant recipients. NEJM. 331:358–363.PubMedCrossRefGoogle Scholar
  12. Busuttil RW, Lake JR. 2004. Role of tacrolimus in the evolution of liver transplantation. Transplantation. 77:S44–S51.PubMedCrossRefGoogle Scholar
  13. Calne RY, White DJ, Thiru S, Evans DB, et al. 1978. Cyclosporin A in patients receiving renal allografts from cadaver donors. Lancet. 2:1323–1327.PubMedCrossRefGoogle Scholar
  14. Chan M, pearson GJ. 2007. New advances in antirejection therapy. Curr Opin Cardiol. 22:117–122.PubMedCrossRefGoogle Scholar
  15. Christians U, Sewing KF. 1993. Cyclosporin metabolism in transplant patients. Pharmacol Ther. 57:291–345.PubMedCrossRefGoogle Scholar
  16. Citterio F. 2001. Steroid side effects and their impact on transplantation outcome. Transplantation. 72:S75–S80.PubMedGoogle Scholar
  17. Contreas M, deSilva M. 1994. The prevention and management of the hemolytic disease of newborn. J Royal Soc Med. 87:256–258.Google Scholar
  18. Crespo-Leiro MG. 2003. Tacrolimus in heart transplantation. Transplant Proc. 35:1981–1983.Google Scholar
  19. DiPavoda FE. 1990. Pharmacology of cyclosporine (Sandimmune). V. Pharmacological effects on immune function in vitro studies. Pharmacol Rev. 41:373–405.Google Scholar
  20. Eisen HJ, Tuzcu EM, Dorent R, Kobashigawa J. 2003. Everolimus for the prevention of allograft rejection and vasculopathy in cardiac transplant recipients. NEJM. 349:847–858.PubMedCrossRefGoogle Scholar
  21. Fahr A. 1993. Cyclosporin clinical pharmacokinetics. Clin Pharmacokin. 24:472–495.CrossRefGoogle Scholar
  22. Ferry C, Socie G. 2003. Busulfan-cyclophosphamide versus total body irradiation-cyclo-phosphamide as preparative regimen before allogeneic hematopoietic stem cell trans- plantation for acute myeloid leukemia: What have we learned? Exp Hematol. 31:1182–1186.PubMedCrossRefGoogle Scholar
  23. Formica RN, Lorber KM, Friedman AL, Bia MJ, et al. 2004. The evolving experience using everolimus in clinical transplantation. Transplant Proc. 36:495S–499S.Google Scholar
  24. Giebel S, Wojnar J, Krawczyk-Kulis M, Markiewicz M, et al. 2006. Treosulfan, cyclophosphamide and antithymocyte globulin for allogeneic hematopoietic cell transplantation in acquired severe aplastic anemia. Ann Transplant. 11:23–27.PubMedGoogle Scholar
  25. Grinyo JM, Cruzado JM. 2006. Mycophenolate mofetil and sirolimus combination in renal transplantation. Am J Transplant. 6:1991–1999.PubMedCrossRefGoogle Scholar
  26. Guessner RW, Kandaswamy R, Humar A, Gruessner AC, et al. 2005. Calcineurin inhibitor – and steroid free immune suppression in pancreas-kidney and solitary pancreas transplantation. Transplant. 79:1184–1189.CrossRefGoogle Scholar
  27. Gummert JF, Ikonen T, Morris RE. 1999. New immunosuppressive drugs. J Am Soc Nephrol. 10:1366–1380.PubMedGoogle Scholar
  28. Halloran PF. 2004. Immunosuppressive drugs for kidney transplantation. NEJM. 351:2715–2729.PubMedCrossRefGoogle Scholar
  29. Henry ML. 1999. Cyclosporine and tacrolimus: A comparison of efficacy and safety profiles. Clin Transplant. 13:209–220.PubMedCrossRefGoogle Scholar
  30. Hong JC, Kahan BD. 2000. Sirolimus-induced thrombocytopenia and leukopenia in renal transplant recipients: Risk factors, incidence, progression and management. Transplantation. 69:2085–2090.PubMedCrossRefGoogle Scholar
  31. Hosenpud JD. 2005. Immunosuppression in cardiac transplantation. NEJM. 352:2749–2750.PubMedCrossRefGoogle Scholar
  32. Iacono AT, Johnson BA, Grgurich WF, Yossef JG, et al. 2006. A randomized trial of inhaled cyclosporine in lung-transplant recipients. 354:141–150.Google Scholar
  33. Ingelfinger JR, Schwartz RS. 2005. Immunosuppression – the promise of specificity. 353:836–839.Google Scholar
  34. Kahan BD. 1999. The potential role of rapamycin in pediatric transplantation as observed from adult studies. Pediat Transplant. 3:175–180.CrossRefGoogle Scholar
  35. Kahan BD. 2004. FTY720: From bench to bedside. Transplant Proc. 36:531S–543S.Google Scholar
  36. Kappos L, Antel J, Comi G, Montalban X, et al. 2006. Oral fingolimod (FYT720) for relapsing multiple sclerosis. NEJM. 355:1124–1140.PubMedCrossRefGoogle Scholar
  37. Keogh A. 2005. Long term benefits of mycophenolate mofetil after heart transplantation. Transplantation. 79:S45–S46.PubMedCrossRefGoogle Scholar
  38. Kino T, Hatanaka H, Hashimoto M, Nishiyama M, et al. 1987. FK506, a novel immunosuppressant isolated from a streptomyces. I. Fermentation, isolation, and physico-chemical and biological characteristics. J Antibiot. 40:1249–1255.PubMedGoogle Scholar
  39. Kreis H. 1992. Antilymphocytic globulins in kidney transplantation. Kidney Int. 42:S188–S192.CrossRefGoogle Scholar
  40. Krensky AM, Strom TB, Bluestone JA. 2005. Immunomodulators: Immunosuppressive agents, tolerogens and Immunostimulants. In: Brunton LL, Ed. Goodman and Gilman’s, the Pharmacological basis of Therapeutics, 11th edition, The McGraw-Hill Companies.Google Scholar
  41. Larsen CP, Knechtle SJ, Adams A, Pearson T, et al. 2006. A new look at blockade of T cell costimulation. A therapeutic strategy for long term maintenance immunosuppression. Am J Transplant. 6:876–883.PubMedCrossRefGoogle Scholar
  42. Liu J, Farmer J, Lane W, Friedman J, et al. 1991. Calcineurin is a common target of cyclophilin-cyclosporin A and FKBP-FK506 complexes. Cell. 66:807–815.PubMedCrossRefGoogle Scholar
  43. Losa Garcia JE, Mateos RF, Jimenez A, Salgado MJ, et al. 1998. Effect of cyclosporin A on inflammatory cytokine production by human alveolar macrophages. Resp Med. 92: 722–728.CrossRefGoogle Scholar
  44. MacDonald AS. 2003. Rapamycin in combination with cyclosporine or tacrolimus in liver, pancreas and kidney transplantation. Transplant Proc. 35:2015–2085.Google Scholar
  45. Mizutami E, Narimatsu H, Murata M, Tomita A, et al. 2007. Successful second cord blood transplantation using fludarabine and cyclophosphamide as a preparative regimen for graft rejection following reduced intensity cord blood transplantation. Bone Marrow Transplant. 40:85–87.CrossRefGoogle Scholar
  46. Neumayer HH. 2005. Introducing everolimus (Certican) in organ transplantation: An overview of preclinical and early clinical developments. Transplantation. 79:S72–75.PubMedCrossRefGoogle Scholar
  47. Perkins JD. 2006. Steroid use in liver transplantation: None, perioperative or full course. Liver Transplant. 12:1294–1295.Google Scholar
  48. Raught B, Gingras AC, Sonenberg N. 2001. The target of rapamycin (TOR) proteins. Proc Natl Acad Sci USA. 98:7037–7044.Google Scholar
  49. Reichenspurner H. 2005. Overview of tacrolimus based immunosuppression after heart or lung transplantation. J Heart Lung Transplant. 24:119–130.PubMedCrossRefGoogle Scholar
  50. Rhen T, Cidlowski JA. 2005. Antiinflammatory action of glucocorticoids – new mechanisms for old drugs. NEJM. 353:1711–1723.PubMedCrossRefGoogle Scholar
  51. Rippin SJ, Serra AL, Marti HP, Wuthrich RP. 2007. Six year followup of azathioprine and mycophenolate mofetil use during the first six months of renal transplantation. Clin Nephrol. 67:374–380.PubMedGoogle Scholar
  52. Sanchez T, Estrada-Hernandez T, Paik JH, Wu MT, et al. 2003. Phosphorylation and action of the immunomodulator FTY720 inhibits vascular endothelial cell growth factor-induced vascular permeability. J Biol Chem. 278:47281–47290.PubMedCrossRefGoogle Scholar
  53. Schmeding M, Newmann UP, Neuhaus R, Neuhaus P. 2006. Mycophenolate mofetil in liver transplantation – Is monotherapy safe? Clin Transplant. 20:75–79.PubMedCrossRefGoogle Scholar
  54. Schulak JA. 2004. The steroid immunosuppression in kidney transplantation: A passing era. J Surg Res. 117:154–162.PubMedCrossRefGoogle Scholar
  55. Sehgal SN. 2006. Rapamune (RAPA, rapamycin, sirolimus) mechanism of action immunosuppressive effect results from blockade of signal transduction and inhibition of cell cycle progression. Clin Biochem. 39:484–489.CrossRefGoogle Scholar
  56. Socie G, Clift RA, Blaise D, Devergie A, et al. 2001. Busulfan plus cyclophosphamide compared with total-body irradiation plus cyclophosphamide before marrow transplantation for myeloid leukemia: Long term followup of four randomized studies. Blood. 98:3569–3574.PubMedCrossRefGoogle Scholar
  57. Starzl TE, Klintmalm GB, Porter KA, Iwatsuki S. 1981. Liver transplantation with use of cyclosporin a and prednisone. NEJM. 305:266–269.PubMedCrossRefGoogle Scholar
  58. Sykes A. 2006. Inhaled cyclosporine may increase survival after lung transplantation. Thorax. 61:305–305.CrossRefGoogle Scholar
  59. Tanabe K, Tokumoto T, Ishida H, Ishikawa N, et al. 2004. Excellent outcome of ABO-incompatible living kidney transplantation under pre transplantation immunosuppression with tacrolimus, mycophenolate mofetil and steroid. Transpl Proc. 36:2175–2177.Google Scholar
  60. Teraok S, Sato S, Sekijima M, Iwado K, et al. 2005. Comparative study of clinical outcome in kidney transplantation between early steroid withdrawal protocol using basiliximab, calcineurin inhibitor, and mycophenolate mofetil and triple regimen consisting of calcineurin inhibitor, mycophenolate and steroid. Transplant Proc. 37:791–794.Google Scholar
  61. Vincenti F, Larsen C, Durrbach A, Wekerle T, et al. 2005. Costimulation blockade with belatacept in renal transplantation. NEJM. 353:770–781.PubMedCrossRefGoogle Scholar
  62. Vincenti F. 2007. Costimulation blockade – what will the future bring? Nephrol Dial Transplant 22:1293–1296.PubMedCrossRefGoogle Scholar
  63. Webster AC, Lee VW, Chapman JR, Craig JC. 2006. Target of rapamycin inhibitors (sirolimus and everolimus) for primary immune suppression of kidney transplant recipients: A systemic view and meta-analysis of randomized trials. Transplantation. 81:1234–1248.PubMedCrossRefGoogle Scholar
  64. Wente MN, Sauer P, Mehrabi A, Weitz J, et al. 2006. Review of the clinical experience with a modified release form of tacrolimus [FK506E(MR4)] in transplantation. Clin Transplant. 17:80–84.CrossRefGoogle Scholar
  65. Westhoff TH, Schmidt S, Glander P, Liefeld L, et al. 2007. The impact of FTY720 (fingolimod) on vasodilatory function and arterial elasticity in renal transplant patients. Nephrol Dial Transplant. 22:2354–2358.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2008

Authors and Affiliations

  1. 1.Creighton University Medical CenterOmahaUSA

Personalised recommendations